Eli Lilly and Company (LLY) vs Manhattan Associates, Inc. (MANH)
A side-by-side comparison of Eli Lilly and Company and Manhattan Associates, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 11, 2026. Differences are shown without an overall score or investment verdict.
Different business models: LLY is classified in Healthcare; MANH is classified in Technology. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
LLY
Eli Lilly and Company
$1,115.25HealthcareDelayed quote: Sep 11, 2026, 3:59 PM EDT
MANH
Manhattan Associates, Inc.
$201.82TechnologyDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — LLY vs MANH
growth of $100 · dividends reinvested · last 10yLLY +1566.6% (+32.5%/yr)MANH +233.0% (+12.8%/yr)LLY compounded faster over this window
Log scale — wide-divergence pair
LLY MANH
LLY vs MANH: by the numbers
- •LLY is the larger company ($1.05T vs $11.77B market cap).
- •LLY trades at the lower trailing earnings multiple (37.42 vs 57.83 P/E), one valuation lens rather than an overall verdict.
- •LLY converts more revenue to profit (33.53% vs 18.67% net margin).
- •LLY grew revenue faster over the past five years (24.42% vs 12.69% CAGR).
- •LLY pays a dividend (0.60% yield), while MANH has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | LLY | MANH |
|---|---|---|
| P/E ratio | 37.42 | 57.83 |
| Forward P/E | 30.64 | 36.71 |
| P/S ratio | 13.18 | 10.45 |
| P/B ratio | 31.00 | 74.71 |
| EV / EBITDA | 29.91 | 41.45 |
| FCF yield | 1.91% | 3.39% |
Profitability
| Metric | LLY | MANH |
|---|---|---|
| Gross margin | 84.01% | 54.65% |
| Operating margin | 43.92% | 24.33% |
| Net margin | 33.53% | 18.67% |
| ROE | 78.84% | 133.48% |
| ROIC | 27.38% | 90.92% |
Dividends
| Metric | LLY | MANH |
|---|---|---|
| Dividend yield | 0.60% | N/A |
| Payout ratio | 22.45% | N/A |
Growth (annualized)
| Metric | LLY | MANH |
|---|---|---|
| Revenue CAGR (5Y) | 24.42% | 12.69% |
| EPS CAGR (5Y) | 28.88% | 21.59% |
| FCF CAGR (5Y) | 32.91% | 19.51% |
| Total return CAGR (5Y) | 37.46% | 4.78% |
Frequently asked
- Which has the lower trailing P/E, LLY or MANH?
- LLY has the lower trailing P/E: LLY trades at 37.42 and MANH at 57.83. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, LLY or MANH?
- Over the past five years, LLY grew revenue faster — LLY at a 24.42% CAGR versus MANH at 12.69%.
- Does LLY or MANH pay a bigger dividend?
- LLY pays a dividend (0.60% yield), while MANH has no payments in the available dividend history.
- Is LLY or MANH more profitable?
- LLY runs the higher net margin — LLY at 33.53% versus MANH at 18.67%.
- How have LLY and MANH total returns compared?
- Over the past 10 years, LLY delivered 32.58% and MANH delivered 13.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Eli Lilly P/E ratioManhattan Associates P/E ratioEli Lilly dividend yieldEli Lilly ROEManhattan Associates ROEEli Lilly operating marginManhattan Associates operating marginEli Lilly revenue growthManhattan Associates revenue growthEli Lilly free cash flowManhattan Associates free cash flow
Eli Lilly & Manhattan Associates appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 11, 2026.